All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the Lymphoma Coalition

The Lymphoma Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy

Impact of novel treatment options on long-term outcomes in CLL and WM

Jun 6, 2019
Share:

William Wierda, MD Anderson Cancer Center, Houston, US, discusses the impact of novel treatment options on long-term outcomes in chronic lymphocytic leukemia (CLL). He discusses the new standard-of-care of small molecule inhibitor monotherapy, and/or with a CD20 antibody. He also mentions the exciting data on combination approaches utilizing BCL-2 inhibitors with BTK inhibitors which have been shown to induce very good deep remissions in the majority of patients, so much so that it may be possible to consider discontinuing therapy.

Impact of novel treatment options on long-term outcomes in CLL and WM

Share: